Hindun Wilda Risni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hindun Wilda Risni has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Rani Sauriasari
Depok West Java 16424 Clinical and Social Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia
3 shared publications - Em Yunir
Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
2 shared publications - Ruth Brauer
University College London
2 shared publications - Cate Whittlesea
Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK
1 shared publication - Ilil Maidatuz Zulfa
University College London
1 shared publication - Indana Ayu Soraya
Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia
1 shared publication
Latest Publications
- Open Access
- 25 June 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (6) , 1-16
Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis
Calcium channel blockers (CCBs) and statins are commonly combined to prevent cardiovascular diseases (CVDs). However, their concomitant use may lead to drug-drug interactions (DDIs) and increased adverse effects (AEs). This systematic review and meta-analysis aimed to evaluate the evidence of adverse effects (AEs) associated with the calcium channel blockers (CCBs) and statins concomitant use. We searched MEDLINE, Embase, Web of Science, and CENTRAL from database inception to 4 April 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies reporting AEs of CCB-statin combinations compared with CCB or statin treatment in adults. Outcomes assessed included CCBs- and statins-associated AEs, treatment discontinuation, hospitalization, and all-cause mortality. Meta-analyses of similar outcomes were performed to estimate pooled Odds Ratios (OR) with 95% confidence intervals (CI). Of 9,737 articles screened, 20 studies (n = 1,053,198) were included. Peripheral edema, myalgia, and discontinuation were most reported in 11, 7, and 9 studies, respectively. Meta-analyses demonstrated no significant differences in the risk of peripheral edema (OR 1.03, 95% CI 0.14-1.48), myalgia (OR 1.33, 95% CI 0.63-2.79), or discontinuation (OR 0.78, 95% CI 0.50-1.23 for CCB-statin vs. CCB; OR 0.97, 95% CI 0.68-1.38 for CCB-statin vs. statin). However, evidence of other AEs was inconsistent and limited. CCB-statin combination appears generally safe in a short-term use (3 to 6 months). Further research is warranted to clarify the long-term risk of AEs.
- 25 June 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (6) , 1-16
Open AccessRisk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis
Calcium channel blockers (CCBs) and statins are commonly combined to prevent cardiovascular diseases (CVDs). However, their concomitant use may lead to drug-drug interactions (DDIs) and increased adverse effects (AEs). This systematic review and meta-analysis aimed to evaluate the evidence of adverse effects (AEs) associated with the calcium channel blockers (CCBs) and statins concomitant use. We searched MEDLINE, Embase, Web of Science, and CENTRAL from database inception to 4 April 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies reporting AEs of CCB-statin combinations compared with CCB or statin treatment in adults. Outcomes assessed included CCBs- and statins-associated AEs, treatment discontinuation, hospitalization, and all-cause mortality. Meta-analyses of similar outcomes were performed to estimate pooled Odds Ratios (OR) with 95% confidence intervals (CI). Of 9,737 articles screened, 20 studies (n = 1,053,198) were included. Peripheral edema, myalgia, and discontinuation were most reported in 11, 7, and 9 studies, respectively. Meta-analyses demonstrated no significant differences in the risk of peripheral edema (OR 1.03, 95% CI 0.14-1.48), myalgia (OR 1.33, 95% CI 0.63-2.79), or discontinuation (OR 0.78, 95% CI 0.50-1.23 for CCB-statin vs. CCB; OR 0.97, 95% CI 0.68-1.38 for CCB-statin vs. statin). However, evidence of other AEs was inconsistent and limited. CCB-statin combination appears generally safe in a short-term use (3 to 6 months). Further research is warranted to clarify the long-term risk of AEs.
- Open Access
- 24 April 2026
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 66 (2) , e70135
Trends in Government‐Subsidised Menopausal Hormone Therapy Dispensing in Australia Between 2014 and 2023
Menopausal hormone therapy (MHT) is a mainstay treatment for menopausal symptoms. While international studies report rising MHT use, trends in Australia remain unclear. Using a 10% random sample of Pharmaceutical Benefits Scheme (PBS) data from 2014 to 2023, we analysed the prevalence of MHT dispensing among women aged 45–64. Overall prevalence of MHT dispensing remained stable (relative annual change: 0.42%, 95% CI −0.50 to 1.35). Use of transdermal and intrauterine device (IUD) MHT increased (5.89%, 95% CI 3.88–7.91 and 10.22%, 95% CI 9.48–10.95, respectively), and vaginal MHT decreased (−1.47%, 95% CI −2.30 to −0.63), while oral MHT appeared stable (0.66%, 95% CI −0.04 to 1.36). This study offers a clearer understanding of how MHT use in Australia has changed over the last decade.
- 24 April 2026
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 66 (2) , e70135
Open AccessTrends in Government‐Subsidised Menopausal Hormone Therapy Dispensing in Australia Between 2014 and 2023
Menopausal hormone therapy (MHT) is a mainstay treatment for menopausal symptoms. While international studies report rising MHT use, trends in Australia remain unclear. Using a 10% random sample of Pharmaceutical Benefits Scheme (PBS) data from 2014 to 2023, we analysed the prevalence of MHT dispensing among women aged 45–64. Overall prevalence of MHT dispensing remained stable (relative annual change: 0.42%, 95% CI −0.50 to 1.35). Use of transdermal and intrauterine device (IUD) MHT increased (5.89%, 95% CI 3.88–7.91 and 10.22%, 95% CI 9.48–10.95, respectively), and vaginal MHT decreased (−1.47%, 95% CI −2.30 to −0.63), while oral MHT appeared stable (0.66%, 95% CI −0.04 to 1.36). This study offers a clearer understanding of how MHT use in Australia has changed over the last decade.
- Open Access
- 1 April 2024
- Published by International Pharmaceutical Federation (FIP) in Pharmacy Education
- Vol. 24 (2) , 163-171
The effect of cognitive decline on the medication adherence in patients with type II diabetes mellitus
Background: Type II Diabetes Mellitus (T2DM) is a risk factor for decreased cognitive function that is rarely recognised by patients, apart from age and other factors. Objective: This study aims to assess the effect of decreased cognitive function on medication adherence in T2DM patients. Method: This study used a cross-sectional design conducted at the Pasar Minggu Community Health Center, Jakarta, Indonesia. Cognitive function was assessed using the validated Indonesian version of the Montreal Cognitive Assessment (MoCA-Ina) questionnaire. Results: One hundred twenty-seven T2DM patients (75.6% female) with a mean age of 58.69 years were recruited. The proportion of T2DM patients with decreased cognitive function was quite high, namely 61%. The proportion of non-adherent patients in the group with decreased cognitive function (70.6%) was greater than in the normal group (29.4%). Decreased cognitive function significantly affected non-adherence in taking medication with aOR 3.744 (95% CI 1.485–9.442), p = 0.005, after controlling for age, education level, HbA1c value, and comorbid dyslipidemia. Conclusion: Patients with decreased cognitive function are 3.7 times more likely to be non-compliant with medication, regardless of age, education level, HbA1c value, and dyslipidemia. Special management is needed for T2DM patients with decreased cognitive function, such as caregiver assistance, education by pharmacists, and simpler drug regimes.
- 1 April 2024
- Published by International Pharmaceutical Federation (FIP) in Pharmacy Education
- Vol. 24 (2) , 163-171
Open AccessThe effect of cognitive decline on the medication adherence in patients with type II diabetes mellitus
Background: Type II Diabetes Mellitus (T2DM) is a risk factor for decreased cognitive function that is rarely recognised by patients, apart from age and other factors. Objective: This study aims to assess the effect of decreased cognitive function on medication adherence in T2DM patients. Method: This study used a cross-sectional design conducted at the Pasar Minggu Community Health Center, Jakarta, Indonesia. Cognitive function was assessed using the validated Indonesian version of the Montreal Cognitive Assessment (MoCA-Ina) questionnaire. Results: One hundred twenty-seven T2DM patients (75.6% female) with a mean age of 58.69 years were recruited. The proportion of T2DM patients with decreased cognitive function was quite high, namely 61%. The proportion of non-adherent patients in the group with decreased cognitive function (70.6%) was greater than in the normal group (29.4%). Decreased cognitive function significantly affected non-adherence in taking medication with aOR 3.744 (95% CI 1.485–9.442), p = 0.005, after controlling for age, education level, HbA1c value, and comorbid dyslipidemia. Conclusion: Patients with decreased cognitive function are 3.7 times more likely to be non-compliant with medication, regardless of age, education level, HbA1c value, and dyslipidemia. Special management is needed for T2DM patients with decreased cognitive function, such as caregiver assistance, education by pharmacists, and simpler drug regimes.
- Open Access
- 1 April 2024
- Published by International Pharmaceutical Federation (FIP) in Pharmacy Education
- Vol. 24 (2) , 134-139
Analysis of drug-related problems in ischemic stroke in-patients in one Indonesian district hospital
Background: Ischemic stroke is one of the leading causes of death in Indonesia. Appropriate management, including the identification of drug-related problems (DRPs), is needed to prevent disability and death. Objective: This study aimed to analyse DRPs as defined by the Pharmaceutical Care Network Europe (PCNE). Method: This was a cross-sectional research using the medical records of in-patients with ischemic stroke aged >18 years. Result: Out of the 115 patients examined, 51.3% were male, and the mean age was 57.85 + 10.539 years. Exactly 204 cases of DRPs and 175 causes appeared in 101 patients. A total of 58 patients experienced one-to-two problems, and 43 patients experienced more than two problems. The problems domain consists of therapeutic effectiveness (P1, 133(65.2%)), adverse effects (P2, 67(32, 84%)), and medical expenses (P3, 4(1, 96%)). The DRPs mostly involved antihypertension and antiplatelet. The most common cause was a new indication for treatment (C1.9, 51(29.14%)) and drug interactions (C8.1, 48(27.43%)). Multivariate analysis of patient characteristics showed that patients taking more than eight medications were more likely to experience more than two DRPs than those on one-to-four medications (OR 5.593; 95%, CI 1.015-30.812). Conclusion: Most patients experienced one-to-two DRPs with the highest being a potentially suboptimal treatment. Clinical pharmacists are expected to monitor therapy, especially in polypharmacy patients.
- 1 April 2024
- Published by International Pharmaceutical Federation (FIP) in Pharmacy Education
- Vol. 24 (2) , 134-139
Open AccessAnalysis of drug-related problems in ischemic stroke in-patients in one Indonesian district hospital
Background: Ischemic stroke is one of the leading causes of death in Indonesia. Appropriate management, including the identification of drug-related problems (DRPs), is needed to prevent disability and death. Objective: This study aimed to analyse DRPs as defined by the Pharmaceutical Care Network Europe (PCNE). Method: This was a cross-sectional research using the medical records of in-patients with ischemic stroke aged >18 years. Result: Out of the 115 patients examined, 51.3% were male, and the mean age was 57.85 + 10.539 years. Exactly 204 cases of DRPs and 175 causes appeared in 101 patients. A total of 58 patients experienced one-to-two problems, and 43 patients experienced more than two problems. The problems domain consists of therapeutic effectiveness (P1, 133(65.2%)), adverse effects (P2, 67(32, 84%)), and medical expenses (P3, 4(1, 96%)). The DRPs mostly involved antihypertension and antiplatelet. The most common cause was a new indication for treatment (C1.9, 51(29.14%)) and drug interactions (C8.1, 48(27.43%)). Multivariate analysis of patient characteristics showed that patients taking more than eight medications were more likely to experience more than two DRPs than those on one-to-four medications (OR 5.593; 95%, CI 1.015-30.812). Conclusion: Most patients experienced one-to-two DRPs with the highest being a potentially suboptimal treatment. Clinical pharmacists are expected to monitor therapy, especially in polypharmacy patients.
- Open Access
- 1 January 2023
- Published by XMLink in Infection & Chemotherapy
- Vol. 55 (1) , 80-89
Evaluation of the Use of Antimicrobial Therapy for Treating Diabetic Foot Infections in an Indonesia Referral Hospital: A Retrospective Cohort Study
Aviatin M, et al. Infect Chemother. 2023 Mar;55(1):80-89. https://doi.org/10.3947/ic.2022.0084
- 1 January 2023
- Published by XMLink in Infection & Chemotherapy
- Vol. 55 (1) , 80-89
Open AccessEvaluation of the Use of Antimicrobial Therapy for Treating Diabetic Foot Infections in an Indonesia Referral Hospital: A Retrospective Cohort Study
Aviatin M, et al. Infect Chemother. 2023 Mar;55(1):80-89. https://doi.org/10.3947/ic.2022.0084
- Open Access
- 1 January 2022
- Published by XMLink in Infection & Chemotherapy
- Vol. 54 (1) , 125-139
A Systematic Review of Randomized Controlled Trials of Antibiotic Use in Diabetic Foot Ulcer Infections: Focus on Clinical Cure
Pratama V, et al. Infect Chemother. 2022 Mar;54(1):125-139. https://doi.org/10.3947/ic.2021.0144
- 1 January 2022
- Published by XMLink in Infection & Chemotherapy
- Vol. 54 (1) , 125-139
Open AccessA Systematic Review of Randomized Controlled Trials of Antibiotic Use in Diabetic Foot Ulcer Infections: Focus on Clinical Cure
Pratama V, et al. Infect Chemother. 2022 Mar;54(1):125-139. https://doi.org/10.3947/ic.2021.0144